The Fox Focus Fall/Winter 2017 - Page 7

Research A Landmark Study to Measure Parkinson’s MJFF launched the landmark Parkinson’s Progression Markers Initiative (PPMI) observational study in 2010 to identify and validate PD biomarkers. Today PPMI is the most comprehensive Parkinson’s study ever — expanding scientists’ understanding of the disease and pinpointing new ways to test and monitor PD. 1,500+ VOLUNTEERS 33 SITES 11 COUNTRIES 20 INDUSTRY PARTNERS 4 CONTINENTS DIGGING DEEPER TO DEFINE PD The power of the Parkinson’s Progression Markers Initiative (PPMI) lies in its unmatched dataset as a foundation for deep scientific inquiry and collaboration. 4,250+ BLOOD SAMPLES 2,200+ CSF SAMPLES 1 MILLION+ DATA DOWNLOADS 130 BIOSAMPLE 65+ PAPERS 2 TRIALS USING REQUESTS WITH PPMI DATA PPMI FINDINGS 7 Fall/Winter 2017 Scientists are using PPMI to define the “molecular fingerprint” of Parkinson’s disease through state-of-the- art “omics” techniques (e.g., genomics, proteomics). These methods look inside body cells and fluids to identify differences in people with Parkinson’s — data that may help scientists understand what causes PD and make treatments to prevent or stop disease. This fall, MJFF is teaming up with researchers to use PPMI and other studies to expand on this “omics” work. The expanded scope could enable greater discovery, and provide opportunities to compare findings across studies to verify results.